Introduction {#sec1}
============

Generations of biologists have been fascinated by salamander limb and tail regeneration. Important grafting experiments delineated the fundamental tissue interactions involved that provide a rich basis for a molecular understanding of regeneration ([@bib3]; [@bib7]; [@bib46]; [@bib47]; [@bib52]) (for reviews, see [@bib34]; [@bib48]). For example, after limb amputation, cells from the muscle, connective tissue, skeletal, peripheral nerve, and epidermis all contribute to the progenitor cell zone, called the blastema, which will reconstitute all limb tissues. The progenitors from these diverse tissues remain largely separate and show divergent behaviors, for example, during limb patterning ([@bib20]; [@bib35]). Therefore, a mechanistic understanding of regeneration requires the control of gene expression in specific cell types. Furthermore, because genes involved in regeneration may also be implemented during development, inducible gene expression is important.

Although several vertebrate models of regeneration are available, there are compelling reasons to study regeneration in the salamander. First, the graftability of salamander tissue provides a uniquely powerful approach to lineage trace cells and to test cell-autonomous versus -nonautonomous events ([@bib33]; [@bib39]). Second, the distinct anatomy of the zebrafish fin from the tetrapod limb limits what we can infer from fins to limbs ([@bib45]). *Xenopus*, a valuable molecular model of regeneration, regenerates the developing hindlimb only prior to metamorphosis (for review, see [@bib55]). This regeneration occurs before full differentiation and could involve progenitor cell sources distinct from those utilized to regenerate a fully differentiated limb ([@bib6]). Therefore, it is important to study regeneration in multiple vertebrates.

Detailed molecular analysis of regeneration has been difficult because it is an adult phenotype with a complex starting point involving the response of many tissues to injury. It is likely that only a subset of cells in any given adult tissue contributes to the blastema. Electroporation of plasmid DNAs and morpholinos has been used to analyze important phenotypes during salamander limb regeneration, but this technique provides transient, variable transfection ([@bib9]; [@bib22]; [@bib28]). Adenovirus, vaccinia virus, and pseudotyped retrovirus have also been applied, but the limited cargo size and toxicity have limited their use and have not yet been widely adopted ([@bib17]; [@bib31]; [@bib41]; [@bib54]). Sustained expression from genomic integration is extremely important for the study of salamander limb regeneration. Successful germline transgenesis has been reported for axolotl ([@bib44]) and has been applied to the Japanese newt and Iberian ribbed newt ([@bib5]; [@bib14]). Moreover, germline EGFP and nuclear Cherry-expressing transgenic axolotls were used in combination with tissue grafting to provide important proof that the regenerating limb blastema is a mixed population of tissue-restricted progenitors ([@bib20]). For further molecular dissection of regeneration, however, conditional induction of gene expression in a time and/or cell-type-dependent fashion is essential. Recently, Whited and colleagues described a system to induce gene expression in axolotls using an IPTG system, whereas this system is promising for acute control of gene expression, the continuous presence of inducer is required to sustain expression that could limit its use for cell tracking during regeneration ([@bib53]). It is not yet known how well the system can be combined with cell-type-specific control of gene expression. Furthermore, the effectiveness of the system was not shown in germline-transmitted F1 animals where full-genomic integration of the transgene may alter its expression properties. In larval axolotls, full-limb regeneration occurs over 2--3 weeks, whereas in fully adult animals, the process can take over 10 weeks. Therefore, a sustainable gene induction system such as the *Cre/loxP* system would be valuable for regeneration studies, but tamoxifen-inducible systems were characterized as too leaky for axolotl transgenics ([@bib53]).

Here, we describe tissue- and time-dependent control of gene expression in germline transgenic axolotls via *Cre/loxP* methodology. We provide a set of germline transgenic animals driving the GFP reporter behind different cell-type-specific promoters relevant for regeneration research. We further employ *Cre/loxP* to conditionally initiate gene expression in a time and cell-type-specific manner. As a proof of principle for phenotype analysis, we demonstrate the inducible overexpression of the tumor suppressor p16^INK4a^. It has been proposed that the *p16*^*INK4a*^*/ARF* locus first arose in mammals and is not present in the salamander, a potential basis for the restricted regeneration capacities of mammals ([@bib37]). By CRE-mediated induction of *p16*^*INK4a*^, we show that it suppresses axolotl spinal cord regeneration. These tools make the axolotl amenable for molecular analysis of regeneration.

Results {#sec2}
=======

Tissue-Specific Germline Transgenic Reporter Strains {#sec2.1}
----------------------------------------------------

Because grafting experiments indicated that each tissue contributes uniquely to regeneration ([@bib20]), a molecular analysis of regeneration requires controlling gene expression specifically in different tissues. We implemented tissue-specific promoters from different animal species to successfully establish germline transgenic axolotl strains showing faithful, cell-type-specific expression of the EGFP gene ([Table 1](#tbl1){ref-type="table"}; [Figure 1](#fig1){ref-type="fig"}). Transgenic strains were produced by injection of plasmid or BAC DNA into one- to two-cell embryos as previously described ([@bib19]; [@bib44]). Injected animals were grown to larval stages and examined via fluorescence protein expression for the extent of expression. Only animals with apparently greater than 80% expression along the body were raised to sexual maturity and then mated to nontransgenic mates (see [Table 1](#tbl1){ref-type="table"} for numerical details for each transgenic strain). The F1 progenies were examined for EGFP expression in the expected cell/tissue types as live whole mounts. To confirm specificity and penetrance of expression, limbs and tails were cross-sectioned and immunostained for respective proteins. We only propagated strains that showed strict colocalization of the EGFP with the respective marker proteins and no extraneous expression. We found this to be an important aspect of the screening process because random integration of the transgenic constructs leads to position effects that can yield mosaicism in the progeny.

To generate germline transgenic lines expressing EGFP in neurons, we implemented the mouse βIII-tubulin regulatory sequences by injecting a previously characterized mouse BAC construct in which the gene for a *GAP43-EGFP* fusion protein sequence had been integrated with its own poly(A) signal downstream of the coding sequence ([@bib2]). Injection was performed without SceI meganuclease, and 12 animals out of 343 injected eggs showed neural-specific expression over large portions of the body (approximately \>80% of cells) ([Table 1](#tbl1){ref-type="table"}). Six animals were grown up for germline transmission and mated to a nontransgenic mate. One of the animals displayed a germline transmission rate of 24%. [Figure 1](#fig1){ref-type="fig"}A shows whole-mount images of a live F1 progeny showing GFP signal in nerve fibers. To confirm the specificity of expression to neurons, we immunostained tail and limb sections for βIII-tubulin ([Figures S1](#app2){ref-type="sec"}A and S1B available online). Excellent (100%) colocalization of EGFP signal with immunofluorescence signal was observed, confirming the specific expression of the transgene. Abundant expression was observed in the spinal cord (arrow), as well as the dorsal root ganglion (arrowhead) and peripheral nerve tracts (asterisks) ([Figure S1](#app2){ref-type="sec"}A), indicating that central and peripheral neurons expressed the transgene.

For marking of glial cells including oligodendrocytes and Schwann cells, we implemented the mouse CNP promoter ([@bib12]). After coinjection of the construct with SceI meganuclease, we obtained 7 strongly expressing F0 animals out of 758 originally injected. Three were mated, and all showed germline transmission. [Figure 1](#fig1){ref-type="fig"}B shows the nerve tracts expressing EGFP in the limb of a typical live F1 animal. Out of the three mated founders, the F1 progeny of one had uniform EGFP expression in putative Schwann cells and oligodendrocytes, whereas the progeny of the other two founders showed mosaic EGFP expression. The limbs and tails of F1 progeny from the uniform founder were cross-sectioned and immunostained with an anti-MBP antibody confirming high (100%) colocalization of EGFP signal with MBP^+^ structures ([Figures 1](#fig1){ref-type="fig"}B, [S1](#app2){ref-type="sec"}C, and S1D). EGFP expression was observed in both the central spinal cord (arrow) ([Figure S1](#app2){ref-type="sec"}C), as well as in DRG (arrowhead) and peripheral nerve tracts (asterisks) of the tail and limb ([Figures S1](#app2){ref-type="sec"}C and S1D), indicating that oligodendrocytes and Schwann cells expressed the transgene. Higher-magnification confocal imaging of a nerve tract in the limb confirmed expression of EGFP in the nucleus and cytoplasm of MBP^+^ cells wrapping around the axon ([Figure S1](#app2){ref-type="sec"}E).

To label other tissues important in regeneration, such as epidermis, muscle, and cartilage, we employed previously characterized *Xenopus* promoters driving EGFP, namely *Keratin12:EGFP*, *CarAct:EGFP*, and *Col2α1:EGFP* ([@bib18]; [@bib36]; [@bib49]). The *Keratin:EGFP* animals express EGFP exclusively in the skin ([Figures 1](#fig1){ref-type="fig"}C, [S1](#app2){ref-type="sec"}F, and S1G), whereas the *CarAct:EGFP* transgenics show robust expression in the myosin heavy-chain-expressing muscle and not in the PAX7-positive satellite cells, indicating faithful muscle-specific expression ([Figures 1](#fig1){ref-type="fig"}D, [S1](#app2){ref-type="sec"}H, and S1I). The *Col2a1:EGFP* line shows expression in cartilage cells, for example, of the larval limb ([Figure 1](#fig1){ref-type="fig"}E).

To further propagate these confirmed lines, F1 progenies were raised to sexual maturity and crossed with white nontransgenic hosts to check for germline transmission and specific uniform EGFP expression in F2 progeny. The F1 male and females were mated to establish "homozygous" lines that result in 100% transgenic progeny when mated to a nontransgenic animal ([Table 1](#tbl1){ref-type="table"}).

Application: Tracking Neurons and Muscle during Limb Regeneration {#sec2.2}
-----------------------------------------------------------------

The ingrowth of nerves is an essential aspect of limb regeneration ([@bib21]), but the process has so far been followed by quantitative electron microscopy and immunofluorescence. The optical clarity of the "white" axolotl strain allows visualization of fluorescent cells in live animals ([@bib10]). Here, to demonstrate the feasibility of following axonal outgrowth during limb regeneration, we amputated limbs of larval *βIIItub:GAP43-EGFP* animals and followed them over time in the same live animal ([Figures 2](#fig2){ref-type="fig"}A--2C). During regeneration, we observed ingrowth of thin axonal fibers already in the early 6 day blastema ([Figure 2](#fig2){ref-type="fig"}A). Further infiltration of axons was observed by the Notch stage of regeneration ([Figure 2](#fig2){ref-type="fig"}B) and consolidation of larger axonal bundles infiltrating the forming digits at the Palette stage ([Figure 2](#fig2){ref-type="fig"}C). These data indicate that robust innervation occurs early during blastema formation, and fiber termini extend well toward the distal epithelium. In the future, more detailed imaging studies can elucidate the dynamics of nerve-epithelial interactions that are crucial for proper limb outgrowth ([@bib22]; [@bib32]).

Another important aspect of limb regeneration is determination of proximal versus distal identity. It was recently shown that skeletal/connective tissue-derived blastema cells regenerate limb elements only more distal to the amputation plane, whereas muscle-derived blastema cells have the potential to regenerate muscle tissue of all limb segments ([@bib35]). In the previous studies, muscle labeling was performed by grafting of presomitic mesoderm from constitutively expressing *CAGGs:EGFP* donor embryos into white hosts. Here, we demonstrate the utility of the *CarAct:EGFP* transgenic animal for revealing the potency of muscle to regenerate cells in all limb segments. To track muscle versus other limb tissues, a *CarAct:EGFP* animal was first crossed to the *CAGGs:Cherry nuc* animal (expresses nuclear Cherry in all cells) to generate double-transgenic *CarAct:EGFP*; *CAGGs:Cherry nuc* that express both transgenes. Midbud hand blastemas were grafted onto the upper-arm stump of a white host animal, in a classic intercalation assay ([Figure 2](#fig2){ref-type="fig"}D) ([@bib16]; [@bib47]). Limbs of normal morphology regenerated ([Figure 2](#fig2){ref-type="fig"}E). Examination of fluorescence signal showed that the muscle-specific EGFP signal (that comes only from the transplanted wrist blastema) was observed in muscle of upper limb, lower limb, and hand ([Figures 2](#fig2){ref-type="fig"}D and 2E). In contrast, the nuclear Cherry signal, which in whole mount is most noticeable in the skin-derived cells, was largely confined to the hand. These results show that muscle progenitors from a hand blastema can form upper- and lower-arm muscle.

Use of Cre/loxP System for Tissue and Time-Dependent Control of Gene Expression {#sec2.3}
-------------------------------------------------------------------------------

To study regeneration, an inducible expression system is important for two reasons. First, when using genetic fate mapping, irreversible activation of marker expression in a given cell type is important because the cell expressing a given marker gene in the mature tissue may, during regeneration, turn off the marker. Second, when studying gene function, inducible expression is important because genes functioning in regeneration may also have earlier roles in development. Considering the long timescales of regeneration, a system that induces sustained expression would be desirable. We therefore focused on testing the *Cre/loxP* system. We first generated a germline transgenic *loxP* reporter strain where the *CAGGs* promoter drives a floxed *EGFP-STOP* cassette followed by the *Cherry* gene- *CAGGs:LP-EGFP-STOP-LP-Cherry* ([Figure S2](#app2){ref-type="sec"}). A total of 11 putative founders were raised to sexual maturity. Seven were mated to white nontransgenic hosts, and all yielded germline transmission with a frequency in the range of 5.4%--54%. Only one founder had mosaic EGFP expression as determined by cross-sectioning the limbs and tails of F1 progeny and staining the sections with DAPI to ascertain that EGFP is expressed in every cell.

To evaluate whether CRE-mediated recombination can work on the genomically inserted transgene, we electroporated a *Cre* expression plasmid into the mature limb and tail of the F1 progeny of *loxP* reporter. After 3 days, we observed robust Cherry expression only in animals that had received *Cre* plasmid ([Figures S2](#app2){ref-type="sec"}D and S2H), and not in control unelectroporated animals ([Figures S2](#app2){ref-type="sec"}B and S2F). No Cherry expression was observed when PBS and/or empty plasmid (pUC19) was electroporated into the tail and limb of the *loxP* reporter animal. Similarly, no spontaneous Cherry expression was observed after limb/tail amputation and during regeneration of the PBS/pUC19 electroporated animals ([Figure S3](#app2){ref-type="sec"}).

Interestingly, coelectroporation of the split *Cre* constructs ([@bib4]) together also induced robust recombination and Cherry expression, whereas electroporation of the single constructs did not, bringing up the possibility of making CRE activity dependent on expression of two promoters ([Figure S4](#app2){ref-type="sec"}).

Cell-type-Dependent Control of Cre Activity in Sox2^+^ Neural Stem Cells {#sec2.4}
------------------------------------------------------------------------

We next sought to control *Cre* expression in a cell-type-specific manner. We isolated a 15 kb genomic clone for the axolotl *Sox2* gene that is expressed in the neural stem cells of the CNS ([@bib23]; [@bib27]; [@bib56]). The clone included 11.68 kb upstream of the coding sequence, the *Sox2* coding sequence and 2.66 kb downstream sequence of the coding sequence. Recombineering was used to incorporate a *Cre ER*^*T2*^*-T2A-nucGFP* cassette by replacing the *Sox2* coding sequence. The resulting construct was injected into eggs together with SceI meganuclease. *Cre-ER*^*T2*^ is a highly used method for induction of CRE activity via the tamoxifen metabolite, 4-hydroxytamoxifen (4-OHT) ([@bib29]). F1 progeny from a germline-transmitting animal showed robust expression of nuclear GFP in the ventricular, SOX2^+^ cells of the brain ([Figures 3](#fig3){ref-type="fig"}C--3G′). When crossed to the *CAGGs:LP-EGFP-STOP-LP-Cherry* reporter, the F1 progeny displayed strong Cherry expression in the brain even in the absence of tamoxifen, indicating leaky but cell-type-specific activity of the CRE-ER^T2^ ([Figures 3](#fig3){ref-type="fig"}I and 3J). Because recombination was occurring continuously even in the absence of tamoxifen, the distribution of Cherry^+^ cells was broader than the nucGFP because the SOX2^+^ cells and their progeny expressed the Cherry gene ([Figures 3](#fig3){ref-type="fig"}J--3M′). From these experiments, we can conclude that cell-type-specific expression of CRE activity in neural stem cells is achievable but that the CRE-ER^T2^ is not sufficiently stringent for tamoxifen-induced activity, showing spontaneous recombination ([Figure 3](#fig3){ref-type="fig"}).

ER^T2^-Cre-ER^T2^ Fusions Provide Nonleaky Tamoxifen-Inducible Cre-Mediated Gene Expression in Axolotl {#sec2.5}
------------------------------------------------------------------------------------------------------

To achieve tighter temporal induction of CRE activity, we assayed a number of induction systems for driving the *Cre* gene, including *Tet-on/off*, *GBD*, *Gal80*^*ts*^, *Gal4VP16/UAS*, and a double fusion to the *ER*^*T2*^ sequences ([@bib11]; [@bib24]; [@bib25]; [@bib51]), by electroporation of plasmids for these systems into limb tissue. Most systems displayed problems such as leakiness or toxicity. For example, dexamethasone was toxic to the animals. Two versions of the Tet-on system were tested: the Tet-on advanced transactivator (rtTA2^S^-M2) ([@bib50]) yielded significant Cre recombination in the absence of doxycycline ([Figures S5](#app2){ref-type="sec"}A and S5B). The improved reverse tetracycline transactivator (irtTA) fused to the ligand binding domain of mutated glucocorticoid receptor (irtTA-GBD^\*^) ([@bib1]) showed less leakiness than rtTA2^S^-M2, but dexamethasone was toxic ([Figures S5](#app2){ref-type="sec"}C and S5D). The temperature-sensitive repressor Gal80^Ts^ that binds and blocks the Gal4-mediated transcription at 18°C and allows transcription at 30°C has been used in *Drosophila* ([@bib38]). Electroporation of Gal80^Ts^ into the axolotl limb of *loxP* reporter along with Gal4-UAS-Cre still yielded Cre recombination at 18°C ([Figures S5](#app2){ref-type="sec"}E and S5F).

We therefore reexplored the control of CRE by the ERT2 sequences and tamoxifen. As expected, in limbs electroporated with a *CAGGs:Cre-ER*^*T2*^ expression plasmid, we observed strong Cherry expression in the absence of tamoxifen ([Figures S5](#app2){ref-type="sec"}G and S5H). Therefore, we tried a number of means to attenuate the CRE-ERT activity including fusion with a nuclear export signal and fusion with a ubiquitinylation signal, but neither decreased the background activity sufficiently ([Figures S5](#app2){ref-type="sec"}I--S5L). However, we found that the *ER*^*T2*^*-Cre-ER*^*T2*^ fusion ([@bib57]) did elicit tight, tamoxifen-inducible CRE activity, as seen by no Cherry expression after the electroporation of the construct in the absence of tamoxifen ([Figures S5](#app2){ref-type="sec"}M and S5N) but robust expression of Cherry after electroporation and subsequent tamoxifen induction ([Figures S6](#app2){ref-type="sec"}O and S6P). We therefore produced a germline transgenic *CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-nuc-EGFP* (*Cre-2xER*^*T2*^) animal ([Figures 4](#fig4){ref-type="fig"}A and 4B). When double-*CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-nuc-EGFP/+;CAGGs:loxP-EGFP-STOP-loxP-Cherry/+* animals were bred ([Figure 4](#fig4){ref-type="fig"}C), we observed no recombination prior to 4-OHT induction ([Figures 4](#fig4){ref-type="fig"}D and 4F). After a single intraperitoneal injection of 4-OHT, we observed robust Cherry expression as assayed in limb and tail tissue ([Figures 4](#fig4){ref-type="fig"}E and 4G). Some EGFP expression persisted after induction even in Cherry-positive cells. This is presumably due to the loxP reporter harboring multiple integrated copies of the transgene or due to perdurance of the GFP. We conclude that the *ER*^*T2*^*-Cre-ER*^*T2*^ fusion provides tight, temporal control of gene expression in the axolotl.

Tamoxifen-Inducible Expression in CollagenII-Expressing Vertebral Cells {#sec2.6}
-----------------------------------------------------------------------

To combine cell-type-specific and temporal induction of gene expression, we placed the *ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-nuc-EGFP* cassette behind the *Xenopus Col2a1* promoter that drives expression in skeletal cells (see [Figure 1](#fig1){ref-type="fig"}E), and germline-transmitting animals were produced. Five putative founders were raised to sexual maturity, and one transmitted through the germline showing nuclear EGFP expression in cartilage of F1 progeny when crossed with white nontransgenic host. In this animal, the head and tail cartilage showed particularly strong expression of the transgene. The germline-transmitting animal was crossed to the *loxP* reporter animals ([Figure 5](#fig5){ref-type="fig"}A). In the F1, double-transgenic progeny, no Cherry expression was observed in the head or tail tissue prior to tamoxifen administration ([Figures 5](#fig5){ref-type="fig"}B and 5D). After tamoxifen induction, bright areas of Cherry-positive cells were observed in the head cartilage and in the notochord/cartilage ventral to the spinal cord ([Figures 5](#fig5){ref-type="fig"}C and 5E).

In conclusion, we have demonstrated that cell-type and temporal control of gene expression is efficient and possible in germline transgenic axolotl lines. This will be useful to track cells during axolotl regeneration and development.

Use of Tamoxifen-Inducible Cre/loxP System to Overexpress p16^INK4a^ {#sec2.7}
--------------------------------------------------------------------

The *Cre/loxP* system is a potentially powerful tool to test the role of molecular pathways during regeneration by overexpression of genes. It has been proposed that one rationale for the robust regeneration in the salamander is its lack of the growth inhibitor gene products p16^INK4a^/ARF. We therefore aimed to apply *Cre/loxP*-based induction to determining the effect of *p16*^*INK4a*^ overexpression during regeneration. Temporal control of gene expression was important because the p16^INK4a^ may be expected to strongly repress cell division during normal development. To overexpress *p16*^*INK4a*^ during regeneration, we fused the human *p16*^*INK4a*^ sequences with *T2A-Cherry* and cloned the fusion construct behind the floxed GFP cassette (floxed p16-Cherry). In order to elicit induction of *p16*^*INK4A*^ expression just prior to regeneration, this animal was crossed to a 4-OHT-inducible *CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-nuc-EGFP* transgenic animal ([Figure 6](#fig6){ref-type="fig"}A). *p16*^*INK4A*^ gene expression was initiated with a single intraperitoneal injection of 4-OHT. Cherry expression was observed 5 days after 4-OHT induction in double-transgenic animals ([Figure 6](#fig6){ref-type="fig"}C), and *p16*^*INK4A*^ ectopic expression was independently confirmed using an antibody against human p16 (data not shown). Tails from Cherry-expressing and -nonexpressing control animals were amputated, followed, and the length of regenerated spinal cord was measured as a discrete indicator of regeneration ([Figures 6](#fig6){ref-type="fig"}B and 6C). At 4 days after tail amputation, a significant inhibition of spinal cord regeneration was observed in animals overexpressing human p16^INK4A^ ([Figure 6](#fig6){ref-type="fig"}D).

Discussion {#sec3}
==========

Here, we have contributed a number of tools and insights into the use of germline transgenic animals for salamander regeneration research by generating germline transgenic animals for cell-type-specific control of gene expression. By employing BACs, heterologous promoters, and axolotl genomic sequences, we have generated a set of animals that drives EGFP in different cell types of the nervous system---neurons (*βIII-tubulin*), glia (*Cnp*), and neural stem cells (*Sox2*). These will provide an invaluable resource for studying brain and spinal cord, as well as peripheral nerve regeneration in these animals. We have also generated animals driving EGFP in muscle, cartilage, and epidermis.

Importantly, we have combined cell-type-specific expression with tight temporal control of gene expression using the *Cre/loxP* system. These are critical tools for the molecular analysis of regeneration because cells from several different tissues contribute to the blastema and remain as distinct progenitor cell pools during regeneration ([@bib20]). Furthermore, the marker used to initiate gene expression in the mature tissue may not be maintained during regeneration. Therefore, the *Cre/loxP* system is particularly valuable for regeneration studies. A critical aspect of the *Cre/loxP* or any induction system is leakiness of the inducer. We therefore scanned a number of means to tightly induce the CRE activity. In contrast to [@bib53], we observe strict tamoxifen-inducible gene expression when employing the doubly regulated *ER*^*T2*^*-Cre-ER*^*T2*^ sequences in F0 and after germline transmission to F1 in combination with ubiquitous promoters (CAGGs) or a tissue-specific promoter (COL2A1). We can speculate on several sources for the difference in leaky versus nonleaky expression in the two settings. First, we have observed that injection liquids present in the glass microinjection needle (such as plasmid DNAs for transgenesis or tamoxifen for injection into the animals) are often left behind in the micropipette holder after use, and these reagents can be carried over into subsequent injections with new glass microcapillaries via aerosol. Therefore, if several plasmids are screened in sequence, the presence of contaminating *Cre-ER*^*T2*^ DNA from previous injections remaining behind in the micropipette holder and then being transferred to new microcapillaries could have confounded the previous results. Similarly, use of the microinjection device for tamoxifen injection yielded "background" recombination when the DMSO control sample was injected after the tamoxifen samples without cleaning the micropipette holder in between, but not vice versa. We therefore clean the micropipette holder between each round of injections. A second potential source of apparent leakiness for *ER*^*T2*^*-Cre-ER*^*T2*^ systems could be the quality of the local water because the animals are aquatically raised and constantly exposed to water. The presence of estrogen mimics in the animal water supply could confound the results, and therefore, the use of a carefully controlled water supply is recommended.

Another important technical aspect for transgenesis in this system is careful, cellular level monitoring of the germline transmission. Because the transgenes integrate randomly in the genome, position effects result in differences in expression of the same construct among different integrants. We therefore screen the F1 progeny of germline-transmitting strains by histological/immunofluorescence analysis to confirm the specificity and completeness of the expression. For example, when generating constructs driven by the CAGGs promoter, which should be expressed in every cell type, we observe some F0 founders whose progeny show no expression in specific cell types such as satellite cells or neuronal cells. We therefore always drive a fluorescent reporter gene behind the transgene and analyze the tissues of interest for appropriate expression.

We have demonstrated the ability to interrogate gene function during tail regeneration via inducible overexpression of the human *p16*^*INK4a*^ gene. It has been proposed that the *p16*^*INK4a*^*/ARF* locus first arose in mammals and is not present in animals like the salamander, a potential basis for the restricted regeneration capacities of mammals ([@bib37]). Here, we have tested if expression of the *p16*^*INK4a*^ gene represses regeneration when induced ubiquitously prior to regeneration onset. Indeed, we observed a significant retardation of spinal cord regeneration in overexpressing the p16^INK4a^ gene, consistent with an antiregenerative function for this gene. These animals could in the future be used to understand the differing downstream responses in p16^INK4a^-expressing or -nonexpressing cells. These transgenic tools in combination with the growing amount of axolotl sequence data that incorporate next-generation sequencing results from our own and other labs for contig assemblies of the axolotl transcriptome and some genomic sequences ([@bib13]; [@bib30]; [@bib40]; [@bib43]) open up new possibilities to parlay this classical regeneration system into a molecular genetic system to investigate the mechanistic basis of regeneration in a vertebrate and its restriction in other animals.

Experimental Procedures {#sec4}
=======================

Axolotl Care and Transgenesis {#sec4.1}
-----------------------------

Animal experiments were performed after approval by the Landesdirektion Saxony, Board of Animal Welfare. Animals were bred in Dresden, Germany, and kept in local tap water at 18°C. The water quality was controlled every day for temperature, pH, ammonia levels, and water consumption. Juveniles and adult animals were kept in continuous flow towers outfitted with particle filters, charcoal filters, and UV filters. Larvae were kept in small plastic tubs with change of fresh water every second day. Larvae were fed *Artemia* daily, whereas juvenile and adult animals were fed fish pellets. Transgenic axolotls were generated as described ([@bib19]; [@bib44]). Briefly, one-cell-stage embryos were collected and manually dejellied and kept at 4°C until injections were performed. Plasmids that harbored SceI meganuclease target sites flanking the expression cassette were coinjected with the SceI meganuclease enzyme (New England Biolabs). Although the SceI meganuclease increased efficiency of transgenesis as previously described, it was not absolutely necessary for generation of transgenics. Swimming larvae were anesthetized in 0.01% ethyl-*p*-aminobenzoate (benzocaine; Sigma-Aldrich) for screening based on fluorescence and were screened on an Olympus SZX16 stereomicroscope. Selected embryos were raised for sexual maturity (males 7--9 months and females 12--15 months) and mated with nontransgenic white animals to check for germline transmission. The vectors used to generate transgenic axolotls are described in [Table 1](#tbl1){ref-type="table"}.

Generation of AxSox2:Cre-ER^T2^ Transgenic Animals {#sec4.2}
--------------------------------------------------

An *Ambystoma mexicanum* (axolotl) lambda genomic library (Stratagene) was expanded in the lab using the manufacturer's protocol. Axolotl *Sox2* gene-specific primers were designed to screen the primary, secondary, and tertiary pools of the library as described by [@bib15] with minor modifications. Briefly, the 440 pools (50,000 clones each) were screened by PCR, but no colony hybridization was done, rather the tertiary pools were further diluted down to isolate a single positive plaque. The isolated axolotl genomic DNA was recombined into a plasmid backbone, and the resulting plasmid was subjected to a second step of recombineering where the *Sox2* open reading frame was replaced by the *Cre-ER*^*T2*^*-T2A-EGFP-nls* gene using a liquid-recombineering protocol ([@bib42]). The resulting plasmid *AxSox2:Cre-ER*^*T2*^*-T2A-EGFP-nls* was injected into one-cell-stage embryo with SceI meganuclease and allowed to develop normally. Larvae were screened for EGFP expression in brain and raised to sexual maturity.

Generation of CAGGs:loxP-EGFP-STOP-loxP-p16^INK4A^-T2A-Cherry and COL2A1:ER^T2^-Cre-ER^T2^-T2A-EGFP-nls Transgenic Animals {#sec4.3}
--------------------------------------------------------------------------------------------------------------------------

To generate *CAGGs:loxP-eGFP-STOP-loxP-p16*^*INK4A*^*-T2A-Cherry* and *COL2A1:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nls* transgenic axolotls, *Tol2-CAGGs:loxP-EGFP-STOP-loxP-p16*^*INK4A*^*-T2A-Cherry* and *Tol2-COL2A1:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nls* constructs were coinjected with Tol2 transposase mRNA into the fertilized one-cell-stage white axolotl eggs and selected using the methods described above. Immunostaining was performed to confirm expression of human p16^Ink4A^ using a mouse monoclonal antibody against p16 (Santa Cruz Biotechnology; \#sc-56330). To detect collagenII α1-specific expression, a mouse anti-chicken Collagen type II antibody was used (Millipore; \# MAB 8887).

Distal Limb Blastema Transplantation {#sec4.4}
------------------------------------

Blastema donors (5--6-cm axolotls) were double transgenics of the genotype: *Car Act:EGFP; CAGGs:nucCherry*. Recipients were their nontransgenic white siblings. Donors were amputated through the forearm wrist. Nine days later, recipients were amputated through the proximal half of the stylopod, and protruding bones were trimmed. Immediately, the donor's wrist blastema was cut off and transferred in the same proximal-distal orientation onto the recipient's stump. Animals were left asleep on a wet tissue with 0.01% benzocaine for the following 1--3 hr before placing them back into tap water to recover and regenerate lost limb structures.

DNA Electroporation and 4-OHT Injection {#sec4.5}
---------------------------------------

Circular *Cre* expression plasmid DNA (0.5 mg/ml) was electroporated in the limb and/or spinal cord as previously described ([@bib8]; [@bib26]). For 4-OHT injections, larvae were anesthetized in 0.01% benzocaine and weighed. 4-OHT (Sigma-Aldrich; catalog \# H7904 or \#H6278) was diluted in DMSO to obtain a stock of 10 mg/ml. Stock aliquots were stored at −80°C until use. Fast Green (Sigma-Aldrich; F7258) was added to the thawed solution just prior to injection. A total of 50 μg/g body weight of 4-OHT was injected intraperitoneally in the ventral trunk. After injection, larvae were covered with a blanket of wet tissue for hydration for 20--30 min at room temperature until returning them to tap water.

Immunohistochemical Analysis of Transgenic Animals {#sec4.6}
--------------------------------------------------

Tails and limbs of transgenic axolotl larvae were cut and fixed, cryosectioned, and kept at −20°C until immunostained. The cryosections were stained with respective antibodies as previously described by [@bib20].
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![Transgenic Axolotls with Cell-type-Specific Transgene Expression of EGFP\
(A) Live axolotl larva expressing membrane-tethered EGFP in neurons under the control of mouse βIII-tubulin promoter.\
(B) Limb of live transgenic axolotl expressing EGFP in Schwann cells. The transgenic animal is expressing EGFP under the control of mouse CNP promoter and marking all myelin-positive cells in the body.\
(C) *Xenopus Keratin 12* promoter driving EGFP in epidermis of live axolotl. Here, a limb image is shown.\
(D) Fluorescence image of limb on a live animal showing EGFP expression in muscle driven by the *Xenopus Cardiac Actin* (Car Act) promoter.\
(E) Limb of live transgenic axolotl where *Xenopus Col2α1* promoter is driving *EGFP* in cartilage.\
Scale bars, 1 mm (B, D, and E) and 2 mm (A and C). See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![In Vivo Tracking of Nerves and Muscle during Normal and Intercalary Limb Regeneration\
(A--C) Live tracking of growing nerves in a *βIIItub:GAP43-EGFP* transgenic animal. Nerves as seen in a 6 day limb blastema (A), early digit-forming (Notch) stage (B), and late digit (Palette)-regeneration stage (C) of the same animal. The dashed white lines in (A) and (C) represent the amputation plane.\
(D) Scheme of hand blastema transplantation to follow EGFP muscle versus other cell types during intercalary regeneration. A double-transgenic (*CAGGs:Cherrynuc*;*CarAct:EGFP*) hand blastema was transplanted onto an upper-arm stump of a nontransgenic white mutant host and allowed to regenerate.\
(E) Regenerated limb from the double-transgenic hand blastema graft. The white dashed line shows the amputation plane of the host stump (to where the hand blastema was transplanted). Muscle fibers (green) are present in upper-arm regions during intercalary regeneration, whereas the cherry-positive cells largely populate the hand region of the regenerate.\
Scale bars, 100 μm (A), 200 μm (B), 300 μm (C), and 1 mm (E).](gr2){#fig2}

![Neural Stem Cell Expression via *AxSox2:Cre-ER*^*T2*^*-nucGFP* and Marking of Neural Stem Cell Descendents via CRE-Mediated Recombination\
(A) Scheme of double transgenic used to label SOX2^+^ cells in the brain. LoxP reporter (*CAGGs:loxP-EGFP-loxP-Cherry*) was crossed with a transgenic axolotl where the *Cre-ER*^*T2*^ gene is under the control of the axolotl *Sox2* promoter.\
(B) Bright-field image of head of *Sox2: Cre-ER*^*T2*^ transgenic animal line (F1s).\
(C) EGFP fluorescence image of the head shown in (B) showing brain-specific expression.\
(D--G) Immunostaining of head cross-section of *Sox2: Cre-ER*^*T2*^ driver animal. nucGFP expression is seen in (D), SOX2 immunofluorescence is in (E), nuclei are stained for DAPI in (F), and (G) shows the merged image. (G′) Higher-resolution image of inset in (G) showing colocalization of EGFP signal with immunostaining for SOX2 in the ventricular zone of the brain section.\
(H) Bright-field image of head of double-transgenic animal, *AxSox2:Cre-ER*^*T2*^-nucGFP; *CAGGs:loxP-EGFP-loxP-Cherry*.\
(I) Cherry fluorescence image of the head shown in (H). Clear Cherry fluorescence is seen in brain without tamoxifen administration.\
(J--M) Cross-section of head of *AxSox2:Cre-ER*^*T2*^-nucGFP; *CAGGs:loxP-EGFP-loxP-Cherry* showing expression in Cherry (J), SOX2 immunofluorescence (K)-positive cells in the brain. (L) shows DAPI^+^ nuclei, whereas (M) is the merged image. A broader fluorescence is seen compared to the nucGFP signal in the *AxSox2:Cre-ER*^*T2*^-nucGFP driver, indicating that *Sox2*^*+*^ cells have contributed to new neurogenesis in the brain. (M′) Higher-resolution inset of (M) brain section showing Cherry-positive cells in SOX2^+^ cells as well as their putative descendants.\
Scale bars, 2 mm (C and I), 200 μm (G and M), and 30 μm (G′ and M′).](gr3){#fig3}

![Tight Temporal Control of Cre/loxP-Mediated Gene Expression Using the *ER*^*T2*^*-cre-ER*^*T2*^ System\
(A) Schematic diagram of the *Cre* driver. The *CAGGs* promoter is driving the *ER*^*T2*^*-cre-ER*^*T2*^*-T2A-nuc-EGFP* cassette.\
(B) Limb of *CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc* transgenic animal in green and red channel.\
(C) Schema of mating between *CAGGs:loxP-EGFP-loxP-Cherry* and *CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc* animals.\
(D and F) Limb and tail of a double-transgenic (*CAGGs:loxP-EGFP-loxP-Cherry; CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc*) animal showing EGFP and Cherry expression levels before tamoxifen induction.\
(E and G) Robust Cherry expression is observed in limb and tail of double-transgenic (*CAGGs:loxP-EGFP-loxP-Cherry; CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc*) animals after administration of 4-OHT.\
Scale bars, 1 mm (B and D--F) and 500 μm (G). See also [Figures S2](#app2){ref-type="sec"}, [S3](#app2){ref-type="sec"}, [S4](#app2){ref-type="sec"}, and [S5](#app2){ref-type="sec"}.](gr4){#fig4}

![Temporal Induction of Gene Expression in *Co2A1*^*+*^ Cells Using *Col2A1:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc* Transgenic Axolotls\
(A) Scheme of mating between *loxP* reporter animal (*CAGGs:loxP-EGFP-STOP-loxP-Cherry*) and the driver animal (*Col2A1:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc*).\
(B and D) Double-transgenic animal shows no Cherry fluorescence in head (B) and tail (D) before tamoxifen induction. High-exposure times were used for imaging so that overall tissue architecture could be seen.\
(C and E) Double-transgenic head (C) and tail (E) images after tamoxifen induction. Clear Cherry expression is observed only in the skeletal elements of the head and vertebral column in the tail. Half-exposure time from control (C and E) was used.\
(F--I) Cross-section of head showing colocalization of Cherry (F) with Collagen type II antibody staining (G). DAPI delineates nuclei in blue. (I) represents merged image.\
(J) High-resolution image of inset marked in (I) showing Cherry-positive cells associated with Col2A1 staining in head cartilage.\
Scale bars, 2 mm (C, E, and I) and 100 μm (J).](gr5){#fig5}

![Inducible Overexpression of the Cell-Cycle Inhibitor p16^INK4^ Represses Spinal Cord Regeneration\
(A) To overexpress human *p16*^*INK4A*^, a transgenic animal was made where the p16^INK4A^-T2A-Cherry gene was cloned behind a floxed GFP cassette (*CAGGs:loxP-EGFP-STOP-loxP-p16*^*INK4A*^*T2A-Cherry*). This animal was crossed with a transgenic animal where the 4-OHT-inducible *Cre* was driven by the ubiquitous *CAGGs* promoter (*CAGGs:ER*^*T2*^*-Cre-ER*^*T2*^*-T2A-EGFP-nuc*). The progenies of this mating were screened and injected intraperitoneally with 4-OHT and examined live for induction of Cherry expression 5 days later.\
(B and C) Phenotype of single-transgenic control and double-transgenic experimental animals ectopically expressing p16^INK4A^, following 4-OHT intraperitoneal injection and tail amputation. No Cherry induction is seen in single-transgenic animals (B), whereas the double-transgenic animals induced Cherry expression (C). Images were taken 4 days after tail amputation. White dotted lines indicate the amputation plane; white arrows demarcate the extent of ependymal tube outgrowth.\
(D) Quantitation of the regenerate spinal cord outgrowth in p16^INK4A^-expressing transgenic animals and nonexpressing controls. The length of the ependymal tube is significantly reduced in the p16^INK4A^-expressing animals (paired t-test and the Mann-Whitney U test, p \<0.001).\
Scale bars, 1 mm (B and C).](gr6){#fig6}

###### 

Summary of Germline Transgenic Axolotls

  Genotypes                              Germline Transmission Rate (No. of Founders Raised and Mated/No. that Went Germline)   Details of Constructs                                                            References
  -------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ------------
  **Ubiquitous Transgenic Lines**                                                                                                                                                                                
                                                                                                                                                                                                                 
  CAGGs: EGFP                            15/6                                                                                   CAGGs promoter driving EGFP                                                      [@bib44]
  CAGGs: CherryNuc                       19 Raised and 4 mated/4                                                                CAGGs promoter driving nuclear Cherry                                            [@bib20]
  CAGGs: LP-EGFP-LP-Cherry               11 Raised and 7 mated/7                                                                CAGGs promoter driving floxed EGFP cassette followed by Cherry                   
  CAGGs: LP-EGFP-LP-Tomato               20 Raised and 2 mated/2                                                                CAGGs promoter driving floxed EGFP cassette followed by Tomato                   
  CAGGs: LP-EGFP-LP-p16-T2A-Cherry       9 Raised and 4 mated/2                                                                 CAGGs promoter driving floxed EGFP cassette followed by p16^INK4A^ and Cherry    
  CAGGs: ER-Cre-ER-T2A-EGFP-nuc          3/3                                                                                    CAGGs promoter driving ert2-Cre-ert2 and nuclear EGFP                            
                                                                                                                                                                                                                 
  **Tissue-Specific Transgenic Lines**                                                                                                                                                                           
                                                                                                                                                                                                                 
  B3Tubulin: EGFP                        6/1                                                                                    Mouse βIII-tubulin BAC with membrane localized EGFP                              [@bib2]
  CNP: EGFP                              7 Raised and 3 mated/3                                                                 Mouse 2′3′-cyclic nucleotide 3′-phosphodiesterase (CNP) promoter driving EGFP    [@bib12]
  Col2a1: EGFP                           6/2                                                                                    *Xenopus* collagen 2 α 1 promoter driving EGFP                                   [@bib18]
  KRT12: EGFP                            4/1                                                                                    *Xenopus* keratin 12 promoter fragment driving EGFP                              [@bib49]
  CarAct: EGFP                           8 Raised and 3 mated/3                                                                 *Xenopus* cardiac actin promoter driving EGFP                                    [@bib36]
  AxSox2:cre-ert2-T2A-GFP                5/1                                                                                    Axolotl Sox2 genomic clone with cre-ert2-GFP-nuc integrated instead of the ORF   
  Col2A1:ER-Cre-ER-T2A-EGFP-nuc          5/1                                                                                    *Xenopus* Col2A1 promoter driving ert2-Cre-ert2 and nuclear EGFP                 [@bib18]

[^1]: Present address: Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA 94158-2156, USA
